News
BDRX
1.060
+7.07%
0.070
Biodexa Pharmaceuticals Has Been Granted U.S. Patent Number 12,011,445 Titled "Prevention Of Pancreatic Cell Degeneration (For The Treatment Of Type I Diabetes)". This Patent Is Licensed From Melior Pharmaceuticals
Benzinga · 5d ago
Weekly Report: what happened at BDRX last week (0610-0614)?
Weekly Report · 6d ago
Biodexa Shareholders Approve Key Resolutions
TipRanks · 06/13 14:28
Results of Annual General Meeting
Barchart · 06/13 08:35
Biodexa Pharmaceuticals Presents 12-Month Phase 2 Clinical Trial Results Of eRapa In Familial Adenomatous Polyposis To Be Presented At The Biennial InSIGHT 2024 Meeting
Twelve month Phase 2 Clinical Trial Results of eRapa in Familial Adenomatous Polyposis to be Presented at Prestigious Biennial InSIGHT 2024 Meeting in Barcelona on June 22, 2024. Biodexa Pharmaceuticals PLC is developing a pipeline of innovative products for the treatment of diseases with unmet needs.
Benzinga · 06/10 12:31
Weekly Report: what happened at BDRX last week (0603-0607)?
Weekly Report · 06/10 11:07
Biodexa Pharmaceuticals files to sell 2.49B ordinary shares for holders
Seeking Alpha · 06/06 20:17
Biodexa Pharmaceuticals Highlights Phase 2 Data Results For eRapa
After the first six months, eRapa appeared to be safe and well-tolerated. The drug has a 24% reduction in the total polyp burden compared with baseline. It also has an 83% non-progression rate in stopping the growth of polyps.
Benzinga · 06/03 12:23
Weekly Report: what happened at BDRX last week (0527-0531)?
Weekly Report · 06/03 11:09
Biodexa Pharmaceuticals Unveils Series G Warrant
TipRanks · 05/28 22:01
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Reshape Lifesciences (NASDAQ:RSLS) shares rose to $ during Tuesday's after-market session. The company's market cap stands at $ million. Losers Sharecare and Sharps Technology also decreased in value during the session.
Benzinga · 05/28 20:31
Weekly Report: what happened at BDRX last week (0520-0524)?
Weekly Report · 05/27 11:14
DQ, BNED and BDRX among pre-market losers
On the Move DQ, BNED and BDRX among pre-market losers. Barnes & Noble Education (BNED) -38%; MGO Global (MGOL) -29%. National Grid Plc (NGG) -9% after FY earnings release.
Seeking Alpha · 05/23 12:24
Nasdaq Falls Over 100 Points; TJX Posts Upbeat Q1 Results
The TJX Companies, Inc. Reported better-than-expected first-quarter financial results on Wednesday. Health care shares rose by on Wednesday; energy shares fell by 2%. The Nasdaq Composite fell over 100 points on Wednesday, with the Dow and S&P 500 also trading lower. Akoustis Technologies, Inc., shares shot up 127% after the company reported better than expected results.
Benzinga · 05/22 18:32
12 Health Care Stocks Moving In Wednesday's Intraday Session
IGM Biosciences shares increased by to $ during Wednesday's regular session. Akso Health Group stock moved upwards by $ during the session. Biodexa Pharmaceuticals shares declined by $ during the same period. LifeStance Health Gr (NASDAQ:LFST) shares decreased by $.
Benzinga · 05/22 16:31
Gold Down Over 1%; Williams-Sonoma Posts Strong Earnings
Stocks traded mixed midway through trading on Wednesday. The Dow traded down to 39, the NASDAQ rose to 16 and the S&P 500 fell to 5. Williams-Sonoma, Inc. Reported better-than-expected first-quarter earnings. Information technology shares rose by on Wednesday; energy shares fell. Asian markets closed mixed.
Benzinga · 05/22 16:17
CureVac, Oragenics, IGM Biosciences among healthcare movers
Seeking Alpha · 05/22 14:00
Biodexa Pharmaceuticals Launches Series G Warrants
TipRanks · 05/22 13:58
US Stocks Mixed; Target Posts Downbeat Earnings
The Dow Jones index traded down around 20 points on Wednesday. Target Corp reported weaker-than-expected first-quarter earnings. Akoustis Technologies, Inc. Shares shot up 222% to $ after the company reportedly floated the probability of bankruptcy. Energy shares fell by on Wednesday, while industrials shares rose. Asian markets closed mixed on Wednesday; European shares were lower.
Benzinga · 05/22 13:55
Biodexa Pharmaceuticals Stock Is Tumbling Wednesday: What's Going On?
Biodexa Pharmaceuticals Plc announced $7 million in gross proceeds from warrant exercises. The company's shares rallied more than 83% on Tuesday after the company announced positive findings from a clinical trial of eRapa. BiodexA shares are trading lower on Wednesday.
Benzinga · 05/22 13:31
More
Webull provides a variety of real-time BDRX stock news. You can receive the latest news about Biodexa Pharmaceuticals plc through multiple platforms. This information may help you make smarter investment decisions.
About BDRX
Biodexa Pharmaceuticals PLC is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. The Q-Sphera technology focuses on long-acting injectables using proprietary three-dimensional (3D) printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics. The MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. The MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility biological potential of Hydrogen (pH), extending available routes of administration, including direct-to-tumor delivery. Its pipeline includes MTX110, MTD201, MTD211 (Schizophrenia, MDD), MTX223, and MTD217.